Expression of Cancer Stem Cell Marker CD44 and Its Polymorphisms in Patients with Chronic Gastritis, Precancerous Gastric Lesion, and Gastric Cancer: A Cross-Sectional Multicenter Study in Thailand
Table 3
Clinicopathological characteristics of gastric cancer associated with CD44 expression (univariate Cox regression model analysis).
Clinicopathological characteristics of gastric cancer ( = 62)
Expression of CD 44 protein (%)
OR (95% CI)
value
Negative
Positive
Location of tumor (%)
(i) Upper
5.12
10.25
0.62 (0.48–0.87)
0.724
(ii) Middle
10.25
15.38
0.87 (0.64–1.09)
0.953
(iii) Lower
7.69
58.84
4.69 (2.01–6.48)
0.01
Tumor size (%)
(i) ≥70 mm
7.69
48.71
5.74 (3.18–8.29)
0.01
(ii) ≤70 mm
20.51
23.07
0.54 (0.42–0.76)
0.834
Histologic type (%)
(i) Differentiated
23.07
17.94
0.73 (0.59–0.92)
0.524
(ii) Undifferentiated
5.12
53.84
8.29 (6.38–12.19)
0.01
Lymphatic invasion (%)
(i) Absent
41.02
7.69
4.21 (1.29–7.74)
0.02
(ii) Present
12.82
38.46
3.39 (1.69–5.58)
0.03
Vascular invasion (%)
(i) Absent
30.76
20.51
0.79 (0.62–1.38)
0.497
(ii) Present
25.64
23.07
0.59 (0.42–1.18)
0.326
Pathological T stage (%)
(i) T1-T2
30.76
28.20
0.82 (0.63–1.13)
0.284
(ii) T3-T4
20.51
46.15
2.19 (1.02–6.29)
0.03
Pathological TNM stage (%)
(i) I
7.69
5.12
0.92 (0.76–1.32)
0.562
(ii) II
17.97
12.82
0.72 (0.51–1.15)
0.481
(iii) III
5.12
28.02
4.49 (1.12–7.84)
0.01
(iv) IV
2.56
20.51
3.32 (1.45–5.890)
0.02
Residual tumor [ = 29] (%)
(i) No
58.97
15.38
2.89 (1.07–4.69)
0.03
(ii) Microscopic
2.56
10.25
1.54 (1.01–4.43)
0.04
(iii) Gross (unresectable)
5.12
7.69
0.74 (0.53–0.91)
0.624
CEA (%)
(i) <5.0 (ng/ml)
28.02
33.33
0.69 (0.58–1.42)
0.573
(ii) ≥5.0 (ng/ml)
17.94
20.51
0.98 (0.75–1.54)
0.782
5 years survival (available = 149) (%)
55.03
14.76
2.83 (1.98–5.62)
0.02
Univariate Cox regression model analysis used to analyze the data. OR, odds ratio; CI, confidence interval. Significance is set at < 0.05.
